Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.

Kevin M PantaloneHiren PatelMaria YuLaura Fernández Landó

Published in: Diabetes, obesity & metabolism (2018)

Dulaglutide 1.5 mg combined with basal or prandial insulin is efficacious for patients with T2D irrespective of age, duration of diabetes or baseline HbA1c.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
end stage renal disease
newly diagnosed
prognostic factors
peritoneal dialysis
clinical trial
randomized controlled trial
metabolic syndrome
open label